BioAtla, Inc. reported a net loss of $59.6 million for the year ended December 31, 2025, compared to a net loss of $69.8 million for the previous year. The company's revenue decreased to $2.0 million in 2025 from $11.0 million in 2024, primarily due to a decrease in revenue recognized under the Context License Agreement. Research and development expenses decreased by $19.5 million to $43.6 million, attributed to lower enrollment in certain clinical trials and the completion of Phase 2 trials for mecbotamab vedotin, ozuriftamab vedotin, and evalstotug. General and administrative expenses also decreased by $4.1 million to $17.7 million, mainly due to lower personnel-related expenses and stock-based compensation.
The company's strategic focus shifted towards exploring and evaluating strategic options to maximize shareholder value, including potential asset sales, licensing transactions, and strategic partnerships. In connection with this strategic review, BioAtla implemented a restructuring plan involving a workforce reduction of approximately 70% to better align resources with near-term priorities. This restructuring is expected to impact the timing and scope of clinical development programs, including the Phase 1 study of BA3182 and the Phase 3 study for ozuriftamab vedotin.
Key operational developments included the ongoing Phase 1 study of BA3182 in advanced adenocarcinoma and the planning for a Phase 3 trial for ozuriftamab vedotin in oropharyngeal squamous cell carcinoma (OPSCC). The company is re-evaluating the timelines for these programs as part of the strategic review. As of December 31, 2025, BioAtla employed 41 individuals.
Looking ahead, BioAtla anticipates that research and development expenses will decrease in the near term due to the completion of Phase 2 trials and the recent workforce reduction. However, the company expects expenses to increase substantially in the long term as it advances its clinical programs and prepares for potential commercialization. The company's ability to continue as a going concern is dependent on securing additional funding through equity or debt financings, strategic collaborations, or other arrangements. As of December 31, 2025, BioAtla's cash and cash equivalents totaled $7.1 million.
About BioAtla, Inc.
BioAtla, Inc. is a clinical-stage biopharmaceutical company specializing in conditionally active biologics (CABs), a novel class of antibody-based therapeutics targeting solid tumor cancers. Its proprietary CAB technology exploits tumor microenvironment acidity to selectively bind cancer cells, reducing off-tumor toxicity. BioAtla develops monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, and CAR-T therapies, focusing on improving cancer treatment efficacy and safety through enhanced tumor specificity.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.